GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Ultra-rapid insulin

Company
Stanford University
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT00575172

    Nippon Ultra-Rapid Insulin and Diabetic Complication Evaluation-Study (NICE-Study)

    Osaka Saiseikai Nakatsu Hospital 346 participants Est. completion 2007-12 1 site
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Status unknown NCT NCT02871089

    Closed Loop From Onset in Type 1 Diabetes

    Not yet reported University of Cambridge 96 participants Est. completion 2024-07-31 7 sites Stand-alone
    Other conditions: Diabetes Mellitus, Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT03959514

    AT247, NovoRapid® and Fiasp® in Glucose Clamp Study

    Not yet reported Arecor Limited 18 participants Est. completion 2019-08-08 1 site
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT04416737

    Evaluating the Benefits of Physiologic Insulin Delivery

    Not yet reported Stanford University 16 participants Est. completion 2023-06-02 1 site Stand-alone
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT05184868

    AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study

    Not yet reported Arecor Limited 24 participants Est. completion 2022-09-09 1 site
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT05257460

    Closing the Loop in Adults With Type 1 Diabetes Under Free Living Conditions (AP@Home04_Phase 4)

    Not yet reported University of Cambridge 28 participants Est. completion 2023-03-25 1 site Stand-alone
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT05653050

    Closing the Loop in People with Type 1 Diabetes

    Not yet reported University of Cambridge 26 participants Est. completion 2024-10-15 4 sites Stand-alone
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT06600776

    Mealtime or Post-meal Dosing of URLi in Medtronic 780G Hybrid Closed Loop System

    Not yet reported Tel-Aviv Sourasky Medical Center 50 participants Est. completion 2025-10-21 1 site
    Other conditions: Type 1 Diabetes (T1D)
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.